Lupus Europe had its annual Convention from November 26-29. We were supposed to all meet in Bratislava, Slovakia, but because of the times we had to change everything into a Convention in the clouds instead. We chose to see this as an opportunity to meet with friends from all around the world, who normally cannot travel to our Convention. Many of our sessions were livestreamed on our Lupus Europe Facebook page, which turned out to be a huge success! At the moment our Convention posts have reached almost 33.000 people around the world!

This year has been marked by the Coronavirus, but we didn´t want a Convention to stand in its shadow. That’s why we had a pre-Convention session about Lupus and Covid with Dr. Pedro Machado, who is an Associate Professor & Consultant Rheumatologist at University College London (UCL) and University College London Hospitals (UCLH), in London, UK. His research interests include the investigation of new therapeutic strategies and the assessment and prediction of outcomes in rheumatic diseases, with a focus on Myositis and Spondyloarthritis. More recently he has developed an interest in COVID-19 and its impact on patients with rheumatic diseases. He is the Chair of the EULAR Standing Committee of Epidemiology and Health Services Research (SCEHSR), and a member of the “EULAR COVID-19 Database” and “COVID-19 Rheumatology Alliance” Steering Committees. Dr. Machado gave us a lot of information about Covid-19 and autoimmunity and answered a lot of questions.

On November 27, we started the day with a review of our 2020 achievements and a presentation of our 2021 Plans. We heard from Lupus groups in the USA, Latin America, Russia, Mauritius and Indonesia. We have much to learn from each other and not least many ways we can collaborate in the future.

Even though we had to meet virtually we still believe it´s important to socialise. We tried to achieve this by having meet and greet sessions after our programme on both the 27th and the 28th. It was really great to talk with all our “old” friends and meet some new ones too!

On the 28th we had a session with Prof. Laurent Arnaud, who is a professor of Rheumatology at the Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases. His main research interests focus around the development and systematic evaluation of biological and immunomodulatory treatments for systemic diseases, with particular interest in the pathogenesis, diagnosis, and treatment of Systemic Lupus Erythematosus and the antiphospholid syndrome. In this session he gave us an elaborate overview of Lupus in 2020 and answered all the questions about Lupus that we never dared ask before.

Later that day our members got the chance to meet some of the partners that Lupus Europe collaborates with on a regular basis. Organisations like EPF, FESCA, ERN ReCONNET, Eurordis, Sjögren Europe and PARE are great resources of information, help us promote the cause of people with autoimmune diseases and influence the European Commission.

We had two closing lectures as parallel sessions on Sunday the 29th. The first parallel session was led by Dr. Meelad Habib about Skin and aesthetic care. Dr Meelad Habib, a young very involved dermatologist, talked about the different presentations of skin. He explained three types of Skin Lupus: acute, subacute and chronic skin Lupus and two very rare skin Lupus: Chilblain and Profundus. He pointed out the characteristics of skin Lupus. He showed a special skin Lupus case (Profundus). He treated it by filling up a dimple caused by Lupus Profundus with the patient´s own body fat. He pointed out that this, or any other cosmetic surgery can only be done, when the patient has an inactive Lupus, and the treatment is done by a multidisciplinary team. He also showed the advice for protection. After the presentation Dr. Habib answered all questions, some of which he couldn’t answer because more study should be done. He suggested one of the questioners to ask the Dermatologist in her/his own hospital.

The second parallel session was by Prof. Richard Furie MD, Chief of the Division of Rheumatology at Northwell Health, New York, is a Rheumatologist whose activities for the last several decades have focused on patient care, physician education, and clinical research in the area of anti-rheumatic drug development. He led us on a journey through the immune system of a Lupus patient and the way new research tries to solve the riddle of the disease. This was a very complex and extremely interesting session, where prof. Furie tried to give us his expectations for the future and answered a ton of great questions from the audience.

Thank you to everyone who joined us in the clouds! All in all, we had a wonderful Convention, but we are really looking forward to seeing you all face-to-face next year in Bratislava! Remember that many of the sessions are still available on the Lupus Europe Facebook page!

Live Facebook Feed

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons
5 days ago
LUPUS EUROPE

Litifilimab, a monoclonal human antibody, has significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo. The phase 2 results have just been published in the The New England Journal of Medicine, which you can find in the "Info Centre" section of our website!

Don't forget to subscribe to be up to date!

www.lupus-europe.org/me-lupus/lupus-europe-info-centre/
... See MoreSee Less

Litifilimab, a monoclonal human antibody, has significantly reduced skin disease activity in people with cutaneous lupus erythematosus (CLE) compared to placebo. The phase 2 results have just been published in the The New England Journal of Medicine, which you can find in the Info Centre section of our website! 

Dont forget to subscribe to be up to date!

https://www.lupus-europe.org/me-lupus/lupus-europe-info-centre/
7 days ago
LUPUS EUROPE

No matter what chronic illness you're living with, having a sense of community and knowing
that you're not alone is helps your daily health and is key to staying motivated.

Follow the community over at @ThisIsLivingToday for tips and advice on wellness, mindfulness and movement. Let’s fight the daily battle together.
... See MoreSee Less

1 week ago
LUPUS EUROPE

We have partnered with @ThisIsLivingToday, a community of people living with chronic conditions with the aim of sharing tips, advice and inspirational stories that help improve health. 🧡

Follow their page @ThisIsLivingToday and hear from individuals who are facing the same challenges you may be facing. Let’s work together and lift each other up.
... See MoreSee Less

We have partnered with @ThisIsLivingToday, a community of people living with chronic conditions with the aim of sharing tips, advice and inspirational stories that help improve health. 🧡

Follow their page @ThisIsLivingToday and hear from individuals who are facing the same challenges you may be facing. Let’s work together and lift each other up.
2 weeks ago
LUPUS EUROPE

Good news!!! Belimumab, a monoclonal antibody, has been approved by the FDA for the treatment of pediatric patients with active lupus nephritis on standard therapy.

Belimumab is the first treatment specifically approved for lupus in more than 50 years.

You can read more about it, plus the results of the phase II, in the link from MedPage Today 👇

www.medpagetoday.com/rheumatology/lupus/99927
... See MoreSee Less

Comment on Facebook

💜

Yes!!!!!!

nu hopen dat Nederland artsen dit overneemt🤔

So happy to hear this

Brilliant

View more comments